The Zhitong Finance App learned that Jinhai Medical Technology (02225) rose more than 10% in early trading. As of press release, it had risen 10% to HK$4.345, with a turnover of HK$117.702 million.
According to the news, on August 3, Jinhai Medical Technology issued an announcement announcing the appointment of Mr. Ma Chengdong as the Group's Chief Marketing Officer, effective from August 3, 2026, for an initial term of one year. According to the announcement, Ma Chengdong will be mainly responsible for the marketing strategy, market access, academic promotion, sales and channel operation of the Group's products, and supervise the commercialization of the Group's medical devices and equipment products.
According to reports, Mr. Ma Chengdong is 55 years old. He graduated from Shanghai Medical University (currently known as Fudan University Shanghai Medical College), majored in clinical medicine, and completed five years of residency training at the Shanghai Cardiovascular Institute. He has more than 25 years of experience in international medical companies. He has worked for General Electric Healthcare (China) Co., Ltd., holding various positions such as technical manager, product manager, regional sales director, Greater China marketing manager, acting general manager of the Greater China region, and general manager of the clinical application and research team; he also served as the senior director of CSOT's strategic marketing department and senior director of commercial excellence at Medtronic (Shanghai) Management Co., Ltd.